Kirin has been granted a patent for an antibody targeting CADM3, useful in brain disease diagnosis and treatment. The antibody or fragments are specified by unique amino acid sequences, enhancing brain accumulation and treatment efficacy. GlobalData’s report on Kirin gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Kirin, Lactobacilli-based drug compositions was a key innovation area identified from patents. Kirin's grant share as of January 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.
Antibody binding to cadm3 for brain disease diagnosis and treatment
A recently granted patent (Publication Number: US11873337B2) discloses an antibody that binds to cell adhesion molecule 3 (CADM3) or its fragments. The antibody is selected from a specific group with defined amino acid sequences for complementarity determining regions (CDRs) of variable domains of heavy and light chains. Additionally, the patent claims the antibody's ability to accumulate in the brain, exhibit an affinity for neurons and nerve tissues, and function as a bispecific antibody binding to CADM3 and an antigen in the brain. The patent also covers various antibody fragments, genetically recombinant antibodies, and different types of antibodies like alpaca, chimeric, humanized, and human antibodies.
Furthermore, the patent includes claims related to fusion antibodies, nucleic acids encoding them, methods for their production, compositions containing them, and their use in detecting brain antigens, diagnosing or treating brain diseases, and enhancing their accumulation in the brain. It also encompasses methods for increasing the amount of antibodies in the brain, hybridomas producing the antibodies, and transformant cells containing nucleic acids encoding the antibodies. The patent's scope extends to methods for producing fusion antibodies, linking them with polymers or functional molecules, and administering them to enhance brain accumulation or treat brain diseases. The patent's comprehensive coverage of antibody-related inventions highlights its potential applications in neuroscience research and therapeutic interventions for brain-related disorders.
To know more about GlobalData’s detailed insights on Kirin, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
